Industry Biopharmaceutical
Sector New drug discovery
Fiscal year end September 30
Shares issued and outstanding 44,660,062*
Stock purchase warrants 1,609,309**
Stock options 5,867,030**
Fully diluted 52,050,127**
Cash ~$25.7 million**
Debt Nil**
Trading symbol AVXL
52-week range $2.45 – $6.64*
Financial statements and filings Anavex’s filings can be found on EDGAR.
Investor relations 1-844-689-3939
ir@anavex.com
Transfer agent Nevada Agency and Trust
50 West Liberty Street, Suite 880
Reno, Nevada 89501
Tel: (775) 322-0626
Fax: (775) 322-5623
Transfer agent email: info@natco.org
Resident Agent email: corpserve@natco.org
Web site: www.natco.org

*  As at May 10, 2018
**As at March 31, 2018
Forms – Reverse Stock Split
Internal Revenue Service (United States) – Form 8937.
Form_8937_(signed)